Conflict 2: Inadequate Monitoring

The individual pharmaceutical companies that participate in IMI provide payments in kind instead of money. But whether and how they do this remains unclear to the public. So who actually monitors the industry?
Foto: © Sebastien Pirlet / Reuters/ REUTERS